8vv1
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Estrogen receptor alpha ligand binding domain in complex with palazestrant== | |
- | + | <StructureSection load='8vv1' size='340' side='right'caption='[[8vv1]], [[Resolution|resolution]] 2.20Å' scene=''> | |
- | + | == Structural highlights == | |
- | + | <table><tr><td colspan='2'>[[8vv1]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8VV1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8VV1 FirstGlance]. <br> | |
- | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.196Å</td></tr> | |
- | [[Category: | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1AEA:(1~{R},3~{R})-2-(2-fluoranyl-2-methyl-propyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole'>A1AEA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
- | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8vv1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8vv1 OCA], [https://pdbe.org/8vv1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8vv1 RCSB], [https://www.ebi.ac.uk/pdbsum/8vv1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8vv1 ProSAT]</span></td></tr> |
- | [[Category: | + | </table> |
- | [[Category: Chawla | + | == Function == |
- | [[Category: | + | [https://www.uniprot.org/uniprot/ESR1_HUMAN ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.<ref>PMID:7651415</ref> <ref>PMID:10970861</ref> <ref>PMID:9328340</ref> <ref>PMID:10681512</ref> <ref>PMID:10816575</ref> <ref>PMID:11477071</ref> <ref>PMID:11682626</ref> <ref>PMID:15078875</ref> <ref>PMID:16043358</ref> <ref>PMID:15891768</ref> <ref>PMID:16684779</ref> <ref>PMID:18247370</ref> <ref>PMID:17932106</ref> <ref>PMID:19350539</ref> <ref>PMID:20705611</ref> <ref>PMID:21937726</ref> <ref>PMID:21330404</ref> <ref>PMID:22083956</ref> |
- | [[Category: | + | == References == |
- | [[Category: | + | <references/> |
- | [[Category: | + | __TOC__ |
- | [[Category: | + | </StructureSection> |
- | [[Category: | + | [[Category: Homo sapiens]] |
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: | + | [[Category: Andersen SE]] |
- | [[Category: | + | [[Category: Barratt S]] |
- | [[Category: | + | [[Category: Chawla R]] |
- | [[Category: | + | [[Category: Duncan A]] |
- | [[Category: | + | [[Category: Fanning SW]] |
- | [[Category: | + | [[Category: Greene GL]] |
- | [[Category: | + | [[Category: Harmon C]] |
- | [[Category: | + | [[Category: Hearn B]] |
- | [[Category: | + | [[Category: Hodges-Gallagher L]] |
- | [[Category: | + | [[Category: Kushner PJ]] |
+ | [[Category: Myles DC]] | ||
+ | [[Category: Ng RA]] | ||
+ | [[Category: Palanisamy G]] | ||
+ | [[Category: Parisian A]] | ||
+ | [[Category: Pena G]] | ||
+ | [[Category: Rich B]] | ||
+ | [[Category: Robello B]] | ||
+ | [[Category: Sapugay J]] | ||
+ | [[Category: Sun R]] | ||
+ | [[Category: Yeghikyan D]] |
Current revision
Estrogen receptor alpha ligand binding domain in complex with palazestrant
|
Categories: Homo sapiens | Large Structures | Andersen SE | Barratt S | Chawla R | Duncan A | Fanning SW | Greene GL | Harmon C | Hearn B | Hodges-Gallagher L | Kushner PJ | Myles DC | Ng RA | Palanisamy G | Parisian A | Pena G | Rich B | Robello B | Sapugay J | Sun R | Yeghikyan D